GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATION
基因组扩增能够耐受样本降解
基本信息
- 批准号:6961398
- 负责人:
- 金额:$ 14.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-01 至 2007-08-31
- 项目状态:已结题
- 来源:
- 关键词:biotechnologybiotransformationcell linecell morphologydata collection methodology /evaluationevaluation /testinggenetic screeninghuman tissuemethylationneoplasm /cancer diagnosisneoplasm /cancer geneticsnucleic acid amplification techniquespolymerase chain reactionsample collectiontechnology /technique developmenttissue /cell preparationtissue resource /registry
项目摘要
DESCRIPTION (provided by applicant): Genomic, epigenetic and gene expression analysis from archived formalin-fixed paraffin embedded (FFPE) tissue samples with known clinical outcomes provides a unique opportunity for extraction of genetic information leading to improved cancer diagnosis, prognosis and therapy. However, extensive genotyping or microarray profiling on homogeneous cell populations within these samples often requires whole genome/mRNA amplification prior to screening. Major hurdles to this process are the introduction of amplification bias and the inhibitory effects of formalin fixation on DNA/RNA amplification. We have developed (RCA-RCA), a novel method based on isothermal rolling-circle amplification, that overcomes the limitations and promises to provide the needed link between obtaining a minute biopsy from partially degraded, FFPE samples and genotyping or micro-array screening. RCA-RCA enables whole genome/mRNA amplification that can be adjusted to the degree of FFPE sample degradation, as this is assessed via real time PCR. Thereby RCA-RCA enables retrieval of the maximum possible amount of information from the degraded sample. In the revised application, apart from adopting the Study Section's recommendations, a further enhancement of RCA-RCA is included, mRCA-RCA. mRCA-RCA amplifies DNA while retaining epigenetic modifications on a genome-wide basis ('whole methylome amplification'), thereby allowing highly expanded detection of methylation in fresh or FFPE samples. The R21 phase will examine the maximum capabilities of the technology and establish criteria for adjusting RCA-RCA to conform to the condition of the specific FFPE sample. The R33 phase will develop the technology for obtaining minute cancer biopsies from FFPE samples, assessing sample quality, and amplifying the whole genome/methylome (DNA) or transcriptome (RNA) without introducing amplification bias. Subsequently it will establish criteria and will validate the utility of the amplified material as input for the most frequently used molecular assays (mutation/SNP detection, microsatellite instability/LOH, array-CGH, expression profiling and methylation detection). By removing problems associated with sample degradation and biases associated with amplification this project will enable application of the newest technologies to the analysis of minute biopsies from archived tissue with known outcomes, thereby accelerating the process of candidate gene discovery.
描述(申请人提供):对已知临床结果的福尔马林固定石蜡包埋(FFPE)存档组织样本的基因组、表观遗传学和基因表达分析为提取遗传信息提供了独特的机会,有助于改善癌症诊断、预后和治疗。然而,对这些样本中的同质细胞群体进行广泛的基因分型或微阵列分析通常需要在筛查之前进行全基因组/信使核糖核酸扩增。这一过程的主要障碍是引入了扩增偏差和福尔马林固定对DNA/RNA扩增的抑制作用。我们开发了一种基于等温滚环扩增的新方法(RCA-RCA),它克服了这些限制,有望在从部分降解的FFPE样本中获得微小活检与基因分型或微阵列筛选之间提供所需的联系。RCA-RCA能够实现全基因组/信使核糖核酸的扩增,可以根据FFPE样本的降解程度进行调整,因为这是通过实时聚合酶链式反应进行评估的。因此,RCA-RCA能够从退化的样本中检索最大可能的信息量。在修订后的申请书中,除了采纳研究科的建议外,还包括了对区域协调-区域协调机制的进一步改进,即区域协调机制--区域协调机制。MRCA-RCA在保持全基因组基础上的表观遗传修饰的同时放大DNA(‘全甲基组扩增’),从而允许在新鲜或FFPE样本中高度扩展的甲基化检测。R21阶段将审查技术的最大能力,并建立调整RCA-RCA的标准,以符合特定FFPE样品的条件。R33阶段将开发从FFPE样本中获取微小癌症活检组织、评估样本质量以及在不引入扩增偏差的情况下放大整个基因组/甲基组(DNA)或转录组(RNA)的技术。随后,它将建立标准,并将验证扩增材料作为最常用的分子分析(突变/SNP检测、微卫星不稳定性/杂合性缺失、阵列-CGH、表达谱分析和甲基化检测)的实用性。通过消除与样品降解相关的问题和与扩增相关的偏差,该项目将使最新技术能够应用于从已知结果的存档组织中进行微小活检的分析,从而加快候选基因发现的进程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
G. Mike Makrigiorgos其他文献
G. Mike Makrigiorgos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('G. Mike Makrigiorgos', 18)}}的其他基金
Comprehensive minimal residual disease tracking in cancer
癌症的全面微小残留病追踪
- 批准号:
9920128 - 财政年份:2018
- 资助金额:
$ 14.62万 - 项目类别:
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes
使用基于核酸酶的突变富集和数字条形码进行最高效率测序
- 批准号:
9355330 - 财政年份:2017
- 资助金额:
$ 14.62万 - 项目类别:
Prognostic potential of low-level mutations in meylodysplastic syndrome
骨髓增生异常综合征低水平突变的预后潜力
- 批准号:
8787719 - 财政年份:2014
- 资助金额:
$ 14.62万 - 项目类别:
Temperature-Tolerant COLD-PCR enables mutation-enriched targeted re-sequencing
耐温 COLD-PCR 可实现突变富集的靶向重测序
- 批准号:
8591934 - 财政年份:2013
- 资助金额:
$ 14.62万 - 项目类别:
High-throughput technology that enables sequencing depth for colorectal CA
高通量技术可实现结直肠 CA 深度测序
- 批准号:
8333344 - 财政年份:2011
- 资助金额:
$ 14.62万 - 项目类别:
High-throughput technology that enables sequencing depth for colorectal CA
高通量技术可实现结直肠 CA 深度测序
- 批准号:
8153972 - 财政年份:2011
- 资助金额:
$ 14.62万 - 项目类别:
Technology for sensitive and reliable mutational profiling in pancreatic cancer
胰腺癌敏感且可靠的突变分析技术
- 批准号:
7795122 - 财政年份:2009
- 资助金额:
$ 14.62万 - 项目类别:
Technology for sensitive and reliable mutational profiling in pancreatic cancer
胰腺癌敏感且可靠的突变分析技术
- 批准号:
7626951 - 财政年份:2009
- 资助金额:
$ 14.62万 - 项目类别:
Technology for sensitive and reliable mutational profiling in pancreatic cancer
胰腺癌敏感且可靠的突变分析技术
- 批准号:
8022903 - 财政年份:2009
- 资助金额:
$ 14.62万 - 项目类别:
相似海外基金
Using Common Fund Datasets to Illuminate Drug-Microbial Interactions
使用共同基金数据集阐明药物-微生物相互作用
- 批准号:
10777339 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Deciphering microbial contribution to androgen bioavailability in castration resistant prostate cancer patients
破译微生物对去势抵抗性前列腺癌患者雄激素生物利用度的贡献
- 批准号:
10573918 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
The landscape of lncRNA biotransformation in aging skeletal muscle cells
衰老骨骼肌细胞中lncRNA生物转化的情况
- 批准号:
23H03155 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis of biotransformation in therapeutic antibody
治疗性抗体的生物转化分析
- 批准号:
23H02649 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Glyphosate impairs glucose homeostasis via gut microbiome induced alterations to bile acid signaling
草甘膦通过肠道微生物组诱导的胆汁酸信号改变损害葡萄糖稳态
- 批准号:
10749326 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Gene-edited liver organoids for predictive hepatotoxicity
用于预测肝毒性的基因编辑肝脏类器官
- 批准号:
10758179 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Metabolism of cancer chemotherapeutics by the human gut microbiome
人类肠道微生物组对癌症化疗药物的代谢
- 批准号:
10635361 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation
通过微生物生物转化减轻外源毒性的新型益生菌
- 批准号:
10707553 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Decoding the role of altered biotransformation pathways in the rapid adaptation of Gulf killifish to legacy pollutants: Using differential population sensitivity to understand chemical vulnerability
解码改变的生物转化途径在海湾鳉鱼快速适应遗留污染物中的作用:利用不同的种群敏感性来了解化学脆弱性
- 批准号:
10729757 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别:
Reverse Metabolomics for the Discovery of Disease Associated Microbial Molecules
用于发现疾病相关微生物分子的反向代谢组学
- 批准号:
10651361 - 财政年份:2023
- 资助金额:
$ 14.62万 - 项目类别: